Anthem Biosciences Limited has informed the Exchange regarding a revised press release for the quarter and financial year ended March 31, 2026.
ANTHEM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.4 pts less than Nifty Midcap 150 and 0.4 pts less than its Pharmaceuticals & Biotechnology peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Anthem Biosciences reported strong FY26 results with consolidated revenue from operations at ₹21,243 Mn, up 15.2% YoY. EBITDA grew 30.8% to ₹9,896 Mn with margin expansion to 43.4% (vs prior year). PAT stood at ₹5,918 Mn, up 31.1% YoY, with PAT margins at 26.0%. Q4FY26 was the highest revenue quarter ever at ₹6,109 Mn, up 26.4% YoY, with PAT jumping 129.8% YoY to ₹1,898 Mn. The company recorded an exceptional item of ₹244 Mn net expense related to India's new labour codes. CRDMO business contributed ₹17,727 Mn (17.7% growth) while Specialty Ingredients contributed ₹3,516 Mn. Net cash position is healthy at ₹13,743 Mn.
Strong operational performance with margin expansion and robust PAT growth signals solid execution. The exceptional labour code item is a one-time charge and does not affect core operations. The company maintains a healthy cash position.